Aim To evaluate the utility of Ki67 as a prognostic marker in a series of patients with node-negative breast cancer untreated with adjuvant systemic therapy.
Methods The cohort consisted of 203 cases treated with breast conserving surgery and radiation only; median follow-up was 183 months (range 156–277 months). An immunohistochemical panel of oestrogen receptor (ER), progesterone receptor (PR), cytokeratin (CK)5/6 and Ki67 and human epidermal growth factor 2 in situ hybridization (HER2-ISH) was performed on the tumour samples. Ki67 scores were evaluable in 193/203 patients (95.1%). The primary outcome was breast cancer specific survival (BCSS).
Results Of the cohort, 29 (14.2%) died of breast cancer. A cut off of 10% separated tumours into a ‘Ki67-low’ (n=70) or ‘Ki67-high’ group (n=123). The breast cancer specific survival was 97.1% and 77.6% for Ki67-low and Ki67-high groups, respectively. Univariate analysis showed that in this lymph node-negative cohort, the predictors for BCSS were tumour size, Ki67, LVI, age and histological grade 3. Multivariable analysis showed that Ki67 index and lymphovascular space invasion were independent predictors of breast cancer death. To examine the utility of Ki67 in assignment of immunohistochemically molecular subtypes, cases were assigned into Luminal A (ER-positive, HER2-negative, Ki67 ≤14%), Luminal B (ER-positive, HER2-negative, Ki67 >14%) and triple negative (ER/PR-negative and HER2-negative, any Ki67). The 15-year breast cancer specific survival was 91.7%, 79.4% and 75.8%, respectively.
Conclusions A statistically significant difference in breast cancer specific survival is seen in groups defined using Ki67 and receptor status, whereas histological grading was not a significant predictor of survival. Ki67 immunostaining provides prognostic information beyond traditionally assessed clinicopathological variables.
- KI 67
- Breast Cancer
- Breast Pathology
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Prognostication and treatment selection for patients with breast cancer is reliant on the assessment of clinical and biological characteristics of breast tumours. Gene expression profiling studies1 ,2 have served to further emphasise the underlying genetic heterogeneity of breast cancers and this is reflected clinically in terms of prognosis and treatment response. The classification of breast cancers into clinically meaningful subgroups on the basis of gene expression profiles is relevant to contemporary oncology practice. There is an immediate need to further refine the prognostic and predictive assessment of breast cancer in order to identify optimal, tailored therapeutic regimens for individual patients and identify those patients in which adjuvant therapy can be avoided. Consequently, there is interest in application of these molecular techniques to routine practice, as evidenced by the publication of several studies defining various molecular signatures as well as the increasing use of commercially available multigene assays.3 Significantly, there is little overlap in terms of individual genes in most of these assays; notably, however, proliferation related genes appear to be a common discriminatory component across all array platforms.3 ,4 Indeed, the most widely used assay, Oncotype DX (Genomic Health, Redwood City, California, USA), calculates a recurrence score derived from the differential expression of 16 discriminatory genes, with MK167 (encoding Ki67) being the most heavily weighted component of the formula.4
In general, time dependant prognostic factors such as tumour size and lymph node metastasis may not declare their associated risk at the time of diagnosis. This is especially relevant in early breast cancer and in a setting of population-based mammographic screening. In this regard, the biological/molecular characteristics of breast cancer assume even greater significance, however, given the prohibitive costs and technical difficulty associated with molecular profiling studies, there is renewed interest in more detailed evaluation of histopathological features including immunohistochemical markers to optimise risk evaluation.
Adjuvant therapy is a confounding factor to understanding the true biological potential of breast cancer. For example, mortality patterns in women with oestrogen receptor (ER)-positive cancers untreated with adjuvant hormone therapy have been shown to be similar to those in women with ER-negative cancers.5 Therefore, there is an advantage in evaluating cancers from patients previously untreated by adjuvant systemic therapy. The aim of this study was to evaluate Ki67 immunohistochemistry as a prognostic marker in isolation and combined with other routinely used biomarkers in a cohort of patients with node-negative breast cancer untreated with adjuvant systemic therapy.
Patients and methods
Individuals included in this study were from a previously described cohort comprising a consecutive series of 421 patients with pathologically lymph node-negative breast cancer who were treated with breast-conserving surgery and postoperative radiotherapy at Westmead Hospital, Westmead, Australia between November 1979 and December 1994.6 All patients underwent axillary dissection and only patients with a minimum of five dissected lymph nodes were included.7 Overall, 203 patients were included in this study on the basis of availability of a paraffin tumour block. The study was conducted with institutional Human Research Ethics Committee approval.
Information on date of death with cancer as the cause of death was obtained from the New South Wales Central Cancer Registry via data linkage performed by the Centre for Health Records and Data Linkage (CHeReL, http://www.cherel.org.au). The creation of the dataset by data linkage followed several processes. Firstly, data from the Central Cancer Registry and Admitted Patient Data Collection was linked by CHeReL using probabilistic methods and Choicemaker software. Variables used in this probabilistic linkage process include name, address, date of birth, sex, country of birth, hospital code and medical record number. Groups with intermediate probabilities (in the range 0.25–0.75) were subject to clerical review. The estimated false positive and false negative rate for this linkage was around 0.5%. The resulting dataset was then linked to the Breast Conservation database (who were treated with breast-conserving surgery and postoperative radiotherapy). The first linkage pass was deterministic and used surname, date of birth, sex and the first initial of given name. Unlinked records from the Breast Conservation Database were then subject to a full probabilistic pass. Thresholds were set so that false positive rates did not exceed 0.5%. Where full identifiers are available, the false negative rate is estimated at 0.5%.
In the absence of death, patients were assumed to be alive as of 31 December 2007, the latest available data for this study. The follow-up period was defined as time from surgery to last date of follow-up for censored cases, or death for complete observation. The median follow-up period for patients was 183 months (range, 156–277 months).
Histopathological review and tissue microarray construction
Details of centralised pathology review have been previously described.6 Documented pathological features included histological type,8 histological grade,9 ,10 and presence of lymphovascular invasion by breast cancer (LVI). Viable tumour samples from different areas of paraffin blocks were selected for inclusion in tissue microarrays (TMA) with three 0.6 mm cores sampled from each case using a manual arrayer (Beecher Instruments, Maryland, USA). Slides, prepared from 4 µm thick sections, were stained with haematoxylin and eosin (H&E) together with an immunohistochemical panel and human epidermal growth factor 2 (HER2) silver in situ hybridisation (ISH; see below).
Ki67 staining was performed on the Ventana Benchmark autostainer (following mild CC1 pretreatment) using the primary antibody clone SP6 (Thermo Fisher Scientific, Fremont, California, USA), at 1:200 dilution with detection using UltraView (Ventana Medical Systems Tucson, Arizona) detection kit. For Ki67 assessment, the slides were scanned at ×400 magnification using a ScanScope CS (Aperio Technologies, Vista, California, USA), and digital images were visualised using ImageScope V.6 (Aperio). Individual positive and negative cells were counted using the manual tag function of Image Pro Plus V.5 (Media Cybernetics, Bethesda, Maryland, USA). All cores were examined and those cores with the greatest number of positive staining tumour cell nuclei were selected for counting, with additional cores counted where less than 1000 cells were present in a single core. All tumour cell nuclei with homogenous/granular or speckled staining or nucleolar staining were regarded as positive, regardless of staining intensity.11 Overall, a median of 1556 tumour cells per case (range 79–12 322), were counted. A total of 10 cases were not assessable for Ki67 due to inadequate tumour sample or unsatisfactory staining. The percentage of total cells that stained positive for Ki67 is reported as the Ki67 index.
Mouse monoclonal antibodies were used for detection of ER (clone 6F11, prediluted, Ventana Medical Systems) and progesterone receptor (PR) (clone 16, prediluted, Ventana Medical Systems), following pretreatment with mild CC1. Detection was performed using UltraView DAB kit (Ventana Medical Systems). Positive nuclear staining of ≥1% of tumour cells of any intensity was regarded as positive.
Cytokeratin (CK)5/6 staining was assessed as a surrogate marker of basal phenotype breast cancers,12 CK5/6 (Cellmarque, Rocklin, California, USA) at 1:100 dilution following pretreatment with mild CC1. Detection was with UltraView detection kit (Ventana Medical Systems). Staining was assessed as positive if ≥1% of cells showed positive cytoplasmic staining of any intensity.
A positive-control section was included in each staining run.
HER2 amplification testing
HER2 amplification was assessed using the single probe INFORM HER2 DNA kit according to manufacturer's instructions. The probe was labelled with dinitrophenol (DNP) used with the Ventana UltraView SISH Detection Kit on the Ventana BenchMark XT automated slide stainer. The repeat-sequence-depleted HER2 DNA probe was denatured at 95°C for 12 min followed by hybridisation at 52°C for 2 h. The HER2 signal was visualised using the rabbit anti-DNP primary antibody and the UltraView SISH Detection Kit. Scoring of HER2 was according to criteria detailed in published guidelines.13 ,14 Cases with a mean of <4 gene copies were designated as negative (non-amplified), cases with 4–6 copies were designated as equivocal, and cases with a mean copy number ≥6 were designated as positive (amplified). In three cases, no result was obtained for HER2 status due to suboptimal staining or inadequate tumour sample.
Statistical analyses were performed using SPSS statistical software (PASW V.18; SPSS, Chicago, Illinois, USA) and SAS statistical software (V.9; SAS Institute Cary, North Carolina, USA). Two-tailed tests with a significance of 5% were used throughout. The Pearson χ2 test was used for comparison of different categories, and if any expected frequency of <5 was obtained, the Fisher's exact test was used. Survival analysis for breast cancer specific survival (BCSS) was carried out using the Kaplan–Meier method for illustration and log-rank tests for statistical significance. BCSS considered only death due to breast cancer as an event within the first 15 years of follow-up. Death from other causes (n=11) or deaths from breast cancer after 15 years (n=3) were censored. Median follow-up was calculated on patients known to be alive.
The sensitivity and specificity were calculated for a number of Ki67 cut-off values and these are shown in table 1. The cut-offs ≥10 had the highest Youden's index of 0.346.15 Accordingly, Ki67 was divided into 2 categories: <10 and ≥10 based on the highest Youden's index.15 The outcome factor was breast cancer survival and the study factors were Ki67 (<10 or ≥10; or continuous), age (<35 years, ≥35 years; or continuous),16 tumour diameter (≤ 10 mm, 11–15 mm, 16–20 mm, or > 20 mm; or continuous), histological grade (1, 2 or 3), ER (positive or negative), LVI (yes or no), mitotic index (<10 or ≥10), CK5/6 (positive or negative), HER2 (positive or negative) and contralateral breast cancer (yes or no).
A preliminary univariate analysis was performed with the Kaplan–Meier method, and groups were compared with the log-rank test. Multivariable Cox regression was used to estimate covariate adjusted HR. The selection criterion for predictor inclusion in multivariable analysis was unadjusted or univariate Cox regression p values ≤0.20.
The study cohort consisted of 203 patients with primary breast cancer, without lymph node involvement, who underwent breast-conserving surgery followed by radiotherapy. No patient received adjuvant systemic therapy. We conducted analyses comparing the subpopulation and whole initial cohort (n=421) for age, grade, LVI and tumour size. There was no significant difference between means of age. Mean age of subpopulation was 50.4 years (SD=10.4), compared to 49.3 years (SD=10.8) of the whole cohort (p=0.24). Similarly, there was no significant difference between means of tumour size (mean=17.0 (SD=7.5) vs mean=15.9 (SD=7.3), p=0.07). Further, there were no significant differences between the proportions of subpopulation and whole cohort for other characteristics: grade (between 0.6% (grade 3) and 1.5% (grade 2, p=0.820)) and LVI (1%, p=0.643). The mean age at diagnosis was 50.4 (range, 28–75) years. Cohort characteristics are summarised in table 2. Invasive ductal carcinomas of no special type accounted for 80% of cases and the tumours were fairly evenly distributed between the three histopathological grades (33.2% grade 1, 34.2% grade 2, 32.6% grade 3). The majority of cases (77.2%) were positive for ER and 69.4% were positive for PR. HER2 was amplified in only 12 patients (6.2%) and equivocal in a further 6 patients. After a median follow-up of 183 months (range, 156–277 months), 43 patients (21%) had died and 32 (16%) of these deaths were related to breast cancer.
Ki67 index as a predictor of breast cancer mortality
Ki67 scores were derived for 193/203 cases. The mean Ki67 index was 22.4% (range 0.07% to 85.7%).
Increasing Ki67 index was associated with increasing breast cancer mortality across the cohort. The sensitivity and specificity of Ki67 index in 5% or 10% increments as a predictor of death from breast cancer is seen in table 1. The highest Youden's index for Ki67 index is seen at ≥10%, where the sensitivity is 0.931. The specificity is seen to increase as the Ki67 count increases with the highest specificity seen when the count is ≥50%, where the specificity is 0.872. A cut-off of ≥10% had the highest Youden's index of 0.346, accordingly, the Ki67 index was used to specify two subgroups: <10% (Ki67-low, n=70) and ≥10% (Ki67-high, n=123).
The striking difference in mortality between patients in the Ki67-low and Ki67-high subgroups is illustrated in figure 1. Only 2 of the 70 patients (3%) in the Ki67-low group died of breast cancer compared with 27 of 123 patients (22%) in the Ki67-high group (p<0.001). The overall 15-year actuarial survival for the Ki67-low subgroup was 97% compared with 78% for Ki67-high (p=0.0003; figure 1). It was further noted that the two breast cancer deaths that occurred in the Ki67-low subgroup were both more than 10 years after diagnosis. In contrast, in the Ki67-high subgroup, 23/27 deaths (85%) occurred within 10 years after diagnosis, with 15 of these occurring within the first 5 years.
Clinicopathological features of Ki67-low and Ki67-high subgroups
The clinicopathological features of Ki67-low and Ki67-high subgroups were distinct (table 2). All of the cases diagnosed in individuals aged <35 years belonged to the Ki67 high subgroup (p=0.004). The Ki67 high subgroup was also associated with larger tumour size (p=0.009), higher grade (p<0.001) and greater proportion of ER-negative tumours (p<0.001). A mitotic index of ≥10 was seen in 51.2% of Ki67-high tumours compared with only 5.7% of Ki67-low tumours (p=<0.001). Expression of CK5/6 was seen more frequently in the Ki67-high subgroup with 40.0% of this group positive compared with 15.9% of the Ki67-low subgroup (p=0.001). All cases of HER2-positive disease were in the Ki67-high group (p=0.004). Patients with a high Ki67 index showed similar rates of mortality in the ER-positive and ER-negative groups, 22.0% and 23.1% (p=0.89), respectively (table 3).
Comparison of Ki67 index and other clinicopathological features as prognostic factors
Univariate analysis showed that in this lymph node-negative cohort, the predictors for BCSS were tumour size, Ki67, LVI, age and histological grade 3(table 4). Histological grade 2, ER, CK5/6, HER2, contralateral breast cancer and mitotic index were not found to be statistically significant predictors of BCSS.
By multivariable analysis with simultaneous adjustment for age, tumour size, grade, ER status, mitotic index >10 and CK5/6 positivity, only Ki67 index (p=0.005) and LVI (p=0.003) remained as independent prognostic factors for BCSS (table 4).
Defining surrogate molecular subtypes using Ki67
A study by Cheang et al17 that specifically compared a gene expression based intrinsic subtype classification of breast cancers with pathological features, reported that a Ki67 score ≥14% distinguished Luminal B from Luminal A, ER-positive HER2-negative tumours. This approach was subsequently supported by the St Gallen 2011 Expert Panel18 as an alternative to molecular subtyping. In order to examine the utility of Ki67 in the context of this classifier, cases were assigned into Luminal A (ER-positive, HER2-negative, Ki67 ≤14%), Luminal B (ER-positive, HER2-negative, Ki67 >14%) and triple negative (ER/PR-negative and HER2-negative, any Ki67) intrinsic subtype categories.
The 15-year breast cancer specific survival of women with luminal A was 91.7%, compared with 79.4% for luminal B (p=0.027) and 75.8% for triple negative (p=0.010), respectively (table 5, figure 2). A statistically significant difference in BCSS was seen between the four subgroups (p=0.009, figure 2). Histological grading, by contrast was not a significant predictor of survival. Histological grading information was available for 201 patients in the cohort, with 67 grade 1, 70 grade 2 and 64 grade 3 tumours. There were 4 deaths (6.0%) from breast cancer in the grade 1 group, 6 (8.6%) in the grade 2 group and 11 (17.2%) in the grade 3 group. The survival differences between the two groups did not reach statistical significance (p=0.106).
The impact of cancer cell proliferation on breast cancer prognosis has been long acknowledged, and in traditional histopathological grading, this assessment is captured by inclusion of a mitotic count score as one of the three components simultaneously assessed. Recently, a more detailed assessment of breast cancer biology has been promoted by molecular profiling studies, which define breast cancer subtypes, as well as individual molecular features and pathways that correlate with prognosis. Cellular proliferation has emerged as a key discriminative feature of malignant phenotype from this work. A labelling index based on immunohistochemical staining of the cell cycle antigen Ki67, is a widely accessible method to make this assessment.
In this study, Ki67 was found to be an independent prognostic factor for 15 year BCSS, in a series of patients with node-negative breast cancer previously untreated with adjuvant systemic therapy. All patients were treated with the standard regime of breast conserving surgery with axillary dissection and radiation therapy. Univariate analysis of Ki67 index along with other routinely assessed clinicopathological variables found LVI, Ki67 index, tumour size, age and histological grade 3 to be statistically significant prognostic factors for BCSS. On multivariable analysis, only Ki67 index and LVI persisted as significant and independent predictors of outcome. Importantly, mitotic rate was not found to be of prognostic value in this cohort, which suggests that Ki67 is a more powerful and sensitive means of assessing tumour proliferation.
Currently there are a number of commercial gene expression based assays available to assess intrinsic breast cancer subtype and gene prognostic scores.4 ,19 Proliferation is a key discriminative component in these assays and it has been demonstrated that similar information can be derived from more routine pathological assessment when a Ki67 score is included. For example, a study by Cheang et al17 that specifically compared a gene expression based intrinsic subtype classification of breast cancers with pathological features, reported that a Ki67 score ≥14% distinguished Luminal B from Luminal A, ER-positive HER2-negative tumours. Similarly, Cuzick et al demonstrated20 that an algorithm based on semiquantitative scores for ER and PR expression, HER2 status a Ki67 score derived from immmunohistochemical staining (‘IHC-4’ score) showed similar prognostic performance to the 21-gene Recurrence Score for ER-positive breast cancer. Taken together these and the current studies illustrate a key role for Ki67 score in current approaches to prognostic assessment of ER-positive breast cancer. Moreover, the value of Ki67 as an individual biomarker for breast cancer prognostication has been reported in a large number of studies and in several meta-analyses.21–24 This validation of Ki67 as a prognostic marker remains robust despite marked variation in study methods, design and cut-off values.
In the current study, a cut off of 10% for Ki67 positivity was found to be prognostically discriminative across the entire cohort. These findings are consistent with those of a recent larger study of 1550 cases by Aleskandarany et al.11 In this study a 10% cut off for Ki67 stratified grade 1 and grade 2 breast cancers into statistically significant prognostic groups. In addition, the study by these authors found that Ki67 index was the strongest predictor of overall and metastasis free survival in univariate and multivariate analysis in grade 2 tumours. Of note about half of their 506 grade 2 tumours, had a Ki67 level of under 10% (‘grade 2a’) and half 10% or more (‘grade 2b’). Grade 2b tumours had a 76% 10-year BCSS rate compared to 92% in the grade 2a cases.
In the current study all the patients in the Ki67-low group had a good prognosis, with few deaths from breast cancer in the cohort at 15 years; those deaths that did occur were seen after 10 years. This is indicative of the long clinical course of these tumours and carries significant implications for patient follow-up protocols. By contrast, Ki67-high tumours showed a steady rate of death from cancer in the first 5–10 years, plateauing thereafter.
None of the women in this study received any form of adjuvant therapy; this presented an opportunity to evaluate the true biological nature of breast carcinoma without the confounding effects of systemic therapy. The marked survival differences in grade 1 tumours in our cohort are partially explained by the lack of hormonal treatment in these women, emphasising the effect of treatment on prognosis. In our study, patients with a high Ki67 index showed similar rates of mortality in the ER-positive and ER-negative groups, 22.0% and 23.1% (p=0.89), respectively (table 3).
Ki67 as an individual biomarker has been confirmed in this and other studies as well as several meta-analyses. In this study we have also demonstrated the utility of Ki67 in classifying breast cancers into surrogate molecular subtypes; this approach was subsequently supported by the St Gallen 2011 Expert Panel as an alternative to molecular subtyping.18 A statistically significant difference in BCSS is seen in the four subgroups defined using Ki67 and receptor status (p=0.009, figure 2). Histological grading in this study, by contrast was not a significant predictor of survival (p=0.106). Some authorities strongly advocate the inclusion of Ki67 along with ER, PR and HER2 as useful for defining breast cancer subtypes with high Ki67 levels warranting consideration of chemotherapy.25 Clearly, pure morphological evaluation of breast cancers is limited by its subjectivity and recently there have been several studies attempting to replicate molecular classifications of breast cancer using immunohistochemistry.26 Ki67 is a good candidate in this respect, and as shown, appears to be more robust and less subjective than mitotic index. This prognostic classification of breast cancer has the advantage of providing information relating to outcome as well as serving as a guide for possible assignment into various therapeutic pathways.
A potential barrier to the clinical utility of Ki67 is the lack of consensus regarding the optimal percentage positive cut-off value to use as well as the methodology that should be adopted. Estimates of Ki67 positivity are likely to be poorly reproducible, and in this study we used an individual cell counting method using scanned images, facilitated by the use of software with a manual tag function to assist with counting. Multiple TMA cores from each tumour were examined to minimise the effects of tumour heterogeneity. In practice however, Ki67 is likely to be used in whole tumour sections. In the study by Aleskandarany et al, ‘hot spots’ were evaluated to account for areas which are likely to drive the biological potential of the tumour, analogous to the approach taken in Scarff–Bloom–Richardson grading where the tumour periphery is scanned for the most mitotically active area to assess the mitotic score. An alternative approach aims to derive a representative score by selecting fields with a range of staining patterns across the section. Clearly, additional work in this area to standardise approaches is required.11
Limitations of the current study include the small sample numbers and the use of TMAs in the assessment, which is unlikely to reflect clinical practice. The study demonstrates however, the utility of an individual cell counting method in objective Ki67 assessment. It also demonstrates the potential ways in which Ki67 can be used as a prognostic marker. This study is best regarded as an exploratory study. Additional studies are required to validate and standardise methodology for Ki67 in routine practice.
In conclusion, this study has confirmed the prognostic value of Ki67 assessment in a cohort of node-negative, systemic treatment-naïve patients with breast cancer with 15 years of follow-up. Analysis of multiple clinicopathological variables revealed that Ki67 index was the most powerful and independent predictor of survival. This cost effective, widely available method provides prognostic information beyond traditionally assessed clinicopathological variables and could enhance treatment planning and prognostication, especially relevant to the challenging area of early breast cancer.
Take home messages
A labelling index based on immunohistochemical staining of the cell cycle antigen Ki67, is a widely accessible method to assess cellular proliferation and is a powerful predictor of survival.
Ki67 assessment provides prognostic information beyond traditionally assessed clinicopathological variables.
Ki67 assessment may have a key role in the prognostic assessment of oestrogen receptor positive breast cancer and provide additional information for therapeutic decisions.
Additional studies are required to validate and standardise methodology for Ki67 in routine practice.
Contributors NP, JB were involved in the concept and development of this study. NP, JB and KB were responsible for initial data collection. NP, AMB, ELS were responsible for pathological analysis. KB and UWJ were responsible for statistical analysis. The first author was responsible for the first draft of the paper and remaining authors for further contribution and review.
Competing interests NP and AMB declare receipt of speaker honoraria and related travel support from Roche Pty Ltd. AMB is a member of the Hoffmann La Roche HER2 Testing Advisory Board. PJP and RLB gratefully acknowledge support from the Cancer Institute NSW (CINSW). RLB is a CINSW Fellow.
Ethics approval Sydney West Local Health District Human Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.